MediciNova Enrolls 200 Patients In SEANOBI-ALS Study

8-K filing — MEDICINOVA INC (MNOV)

Filed: 2026-08-19 AccNo: 0001193125-26-356146 Size: 153 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

The alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected to transform the treatment landscape, with AD04 projected to capture the largest market share by 2036, replacing current leader VIVITROL.

MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma